Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed Hyperlipidaemia.
Journal: European journal of preventive cardiology
Published: May 11, 2026
Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials.
Journal: American journal of preventive cardiology
Published: February 16, 2026
ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.
Journal: The lancet. Gastroenterology & hepatology
Published: January 08, 2026
HMG-CoA Reductase Inhibitors (Statins) May Preserve Hepatic Function and Reduce Portal-Systemic Shunting in Compensated Advanced Chronic Liver Disease: Results From the SHUNT-V Study.
Journal: Clinical and translational gastroenterology
Published: June 04, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
Journal: The New England journal of medicine
Published: May 09, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Journal: Lancet (London, England)
Published: March 24, 2025
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
Journal: Diabetes, obesity & metabolism
Published: October 17, 2024
Development and validation of an eating behavior patient-reported outcome measure in people living with obesity or overweight.
Journal: Obesity (Silver Spring, Md.)
Published: June 25, 2024
Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
Journal: Diabetes, obesity & metabolism
Published: June 20, 2024
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Journal: The New England journal of medicine
Published: May 29, 2024
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Published: November 09, 2023
Last Updated: 09/26/2026